



MERLIONPHARMA

31.08.2022 - New Press Release

31st August 2022

MerLion Pharmaceuticals Announces
Successful FDA Type C Meeting for the
Systemic Application of the Antibiotic
Finafloxacin Against Infections caused by
Burkholderia pseudomallei (Meloidosis)

[All Press Releases](#)

Fighting life-threatening infections

MerLion Pharmaceuticals is addressing one of the most pressing problems in today's medicine: the need for novel and efficient anti-infectives to combat bacterial infections and amongst those in particular infectious diseases caused by antibiotic-resistant bacteria.

MerLion is working for this purpose primarily on developing finafloxacin for the human health sector.

Finafloxacin


Finafloxacin is a next-generation fluoroquinolone antibiotic with unique properties and is one of the safest and fastest acting fluoroquinolones.

Finafloxacin has demonstrated outstanding safety and efficacy in several clinical trials and is currently being developed by MerLion as novel treatment in several indications.

Following successful clinical phase III trials, Xtoro™ (a suspension formulation of finafloxacin) has been granted market approval for the treatment of acute otitis externa (AOE) from the US Food and Drug Administration (FDA) and Health Canada so far.

MerLion is working with the UK Defence Science and Technology Laboratory (Dstl) on a program funded by the US Defense Threat Reduction Agency (DTRA) for the use of finafloxacin against a number of pathogens that are considered to be bioweapon threats.

Finafloxacin has successfully completed a phase II trial for complicated urinary tract infections (cUTIs) including pyelonephritis, using both oral and intravenous routes of administration (tablets and solution for infusion).



Recent Press Releases

31st August 2022

[MerLion Pharmaceuticals Announces Successful FDA Type C Meeting for the Systemic Application of the Antibiotic Finafloxacin Against Infections caused by Burkholderia pseudomallei \(Meloidosis\)](#)

17th February 2022

[Alternative use for novel antibiotic to treat plague and melioidosis](#)

18th May 2021

[MerLion Pharmaceuticals Completes Growth Financing Round](#)

MerLion Pharmaceuticals GmbH
Robert-Rössle-Straße 10
13125 Berlin
Germany

Phone: +49 (0)30 9489-4050

Fax: +49 (0)30 9489-4051

Email: info@merlionpharma.de